Delving into the Latest Updates on ZX-101A with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ZX 101A, ZX-101A, ZX101A

Target

PI3Kγ x PI3Kδ

Action

inhibitors

Mechanism

PI3Kγ inhibitors(Phosphatidylinositol-4,5-Bisphosphate 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaB-Cell Lymphoma+ [1]

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Nanjing Zenshine Pharmaceuticals Co., Ltd.

Active Organization

Nanjing Zenshine Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients with relapsed/refractory hematological malignancies.

Start Date17 Feb 2022

Sponsor / Collaborator

Nanjing Zenshine Pharmaceuticals Co., Ltd.

CTR20213390

/ CompletedPhase 1/2

一项评估ZX-101A治疗复发/难治性血液系统恶性肿瘤患者的I/II期研究

[Translation] A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematologic Malignancies

I期：评估ZX-101A在复发/难治性血液系统恶性肿瘤患者中的安全性和耐受性，并确定ZX-101A的推荐2期剂量（RP2D） II期：评估ZX-101A在复发/难治性外周T细胞淋巴瘤（PTCL）或B细胞非霍奇金淋巴瘤（B-NHL）某一潜在亚型患者中的有效性

[Translation]

Phase I: Evaluate the safety and tolerability of ZX-101A in patients with relapsed/refractory hematological malignancies and determine the recommended Phase 2 dose (RP2D) of ZX-101A Phase II: Evaluate the efficacy of ZX-101A in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or a potential subtype of B-cell non-Hodgkin lymphoma (B-NHL)

Start Date17 Jan 2022

Sponsor / Collaborator

Nanjing Zenshine Pharmaceuticals Co., Ltd.

100 Clinical Results associated with ZX-101A

Login to view more data

100 Translational Medicine associated with ZX-101A

Login to view more data

100 Patents (Medical) associated with ZX-101A

Login to view more data

100 Deals associated with ZX-101A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	China	Nanjing Zenshine Pharmaceuticals Co., Ltd.	07 Mar 2022
Chronic Lymphocytic Leukemia	Phase 2	China	Nanjing Zenshine Pharmaceuticals Co., Ltd.	17 Feb 2022
Small Lymphocytic Lymphoma	Phase 2	China	Nanjing Zenshine Pharmaceuticals Co., Ltd.	17 Feb 2022
B-Cell Lymphoma	Phase 2	China	Nanjing Zenshine Pharmaceuticals Co., Ltd.	17 Jan 2022
Peripheral T-Cell Lymphoma	Phase 2	China	Nanjing Zenshine Pharmaceuticals Co., Ltd.	17 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04504708 (AACR2021)	Phase 1/2	Hematologic Neoplasms	6	ZX-101A	ngebhfruog(cxjmrbvylr) = pjulrctgjk tqwsgzukvb (unbojrfipr )	-	01 Jul 2021
				Anti-PD1 antibody	ngebhfruog(cxjmrbvylr) = lwkvzyigdb tqwsgzukvb (unbojrfipr )